Sorrento Therapeutics and Celularity Aim to Adapt Natural Killer Cell Therapy to Treat Coronavirus
Sorrento Therapeutics (NASDAQ: SRNE) and privately held Celularity announced Wednesday that they are collaborating to develop a natural killer (NK) cell therapy to treat and prevent coronavirus infections, especially the recent outbreak of 2019-nCoV in China. Sorrento's shareholders seem to think the biotech might be spreading itself a little thin with the added program -- its share price had fallen 6.7% as of 11:43 a.m. EST.
Celularity, which is 25% owned by Sorrento, has an NK cell program, CYNK-001, that it's testing for multiple types of cancer. NK cells are part of the immune system and, as the name suggests, their main job is to kill host cells that have been targeted for destruction by other immune cells because they're part of a tumor or have been infected with a virus.
Image source: Getty Images.
Source Fool.com
